Adagene Presents at ESMO Congress in September 2024
Ticker: ADAG · Form: 6-K · Filed: Sep 16, 2024 · CIK: 1818838
| Field | Detail |
|---|---|
| Company | Adagene INC. (ADAG) |
| Form Type | 6-K |
| Filed Date | Sep 16, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: press-release, conference-presentation, regulatory-filing
TL;DR
Adagene presented at ESMO Congress, check the press release for deets.
AI Summary
Adagene Inc. filed a Form 6-K on September 16, 2024, to report its activities for the month of September 2024. The filing includes a press release titled "Adagene Presents Results at ESMO Congress," indicating the company shared its findings at this significant oncology event. The report is filed under the Securities Exchange Act of 1934, with Peter Luo, CEO, signing on behalf of the company.
Why It Matters
This filing signals Adagene's active participation in major scientific conferences, potentially highlighting new research or clinical data that could impact its drug development pipeline and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine report of a press release and does not contain new financial information or significant corporate events that would immediately alter risk.
Key Players & Entities
- Adagene Inc. (company) — Registrant
- September 16, 2024 (date) — Filing Date
- Peter Luo (person) — Chief Executive Officer
- ESMO Congress (event) — Conference where results were presented
FAQ
What specific results did Adagene present at the ESMO Congress?
The filing mentions a press release titled "Adagene Presents Results at ESMO Congress," but the specific results are not detailed within this 6-K form itself. The press release would contain this information.
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers that is required to be filed with the SEC to provide information that the issuer has made or is required to make public pursuant to the laws of its home country or that it has filed or will file with a stock exchange.
Who signed this Form 6-K on behalf of Adagene Inc.?
Peter Luo, the Chief Executive Officer of Adagene Inc., signed the Form 6-K on September 16, 2024.
What is Adagene Inc.'s principal executive office address?
Adagene Inc.'s principal executive offices are located at 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu Province, 215123, People's Republic of China.
Does Adagene Inc. file annual reports under Form 20-F or Form 40-F?
Adagene Inc. indicates it files annual reports under cover of Form 20-F.
Filing Stats: 178 words · 1 min read · ~1 pages · Grade level 13.7 · Accepted 2024-09-16 09:21:10
Filing Documents
- tm2424109d1_6k.htm (6-K) — 9KB
- tm2424109d1_ex99-1.htm (EX-99.1) — 28KB
- tm2424109d1_ex99-1img001.jpg (GRAPHIC) — 13KB
- 0001104659-24-100046.txt ( ) — 56KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. VNET Group, Inc. By: /s/ Peter Luo Name: Peter Luo Title: Chief Executive Officer Date: September 16, 2024 EXHIBIT INDEX Exhibit Description 99.1 Press release tilted “Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody ® ADG126 (Muzastotug) in Combination with KEYTRUDA ® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)”